A Phase I Dose Escalation Study of Autologous Expanded Natural Killer (NK) Cells for Immunotherapy of Relapsed Refractory Neuroblastoma With Dinutuximab +/- Lenalidomide
Latest Information Update: 07 Nov 2024
At a glance
- Drugs Dinutuximab (Primary) ; Lenalidomide (Primary) ; Natural killer cell therapy (Primary)
- Indications Neuroblastoma
- Focus Adverse reactions
- Acronyms NANT
- 05 Nov 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 05 Nov 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Sep 2025.
- 12 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Sep 2024.